Press Release
Press Release
A chronic brain disease called schizophrenia impairs a person's capacity for thought, emotion, and behaviour. The patient may exhibit severely disturbed thinking and behaviour, as well as symptoms like delusions and hallucinations. The schizophrenia drugs market expansion is being driven by growing consumer awareness of mental health.
North America holds a significant market share for this market. According to health reports, approximately 3.7 million Americans, or 1.8% of the adult population between the ages of 18 and 65, experienced schizophrenia spectrum illnesses at some point in their lives. New drug launches and increased R&D for improvements in anti-psychotic medications contribute to the market's expansion of schizophrenia pharmaceuticals in the region.
Continuous research and development support the growth of the market for schizophrenia drug. In January 2024, Arkemas PLC (NASDAQ: ALKS) announced topline findings from a phase 3 open-label extension study. The study evaluated the long-term safety, tolerability, and durability of the treatment effect of LYBALVI® (olanzapine and samidorphan) in patients treated for schizophrenia, schizophreniform disorder, or bipolar I disorder for a maximum of four years after receiving treatment in earlier LYBALVI studies.
In the United States, LYBALVI is licenced for the treatment of adult bipolar I disorder and adult schizophrenia. 523 participants got at least one dosage of LYBALVI in open-label extension research conducted globally, and 35.9% of participants finished the four-year treatment duration. After receiving LYBALVI medication for up to four years, patients' bipolar I disorder or schizophrenia symptoms stayed stable, as indicated by the Clinical Global Impression of Severity (CGI-S) scale (mean change from baseline in CGI-S score of -0.28).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major players in the global schizophrenia drugs market are Eli Lilly and Company, AbbVie Inc., Alkermes PLC, Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., AstraZeneca, Bristol Myers Squibb, Sumitomo Dainippon Pharma Co., Ltd., and Vanda Pharmaceuticals Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapeutic Class |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channels |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.